Syndax is no longer a clinical-stage option on menin biology. It is a two-product commercial company whose second-quarter print tests whether later-line demand is compounding through duration rather than through a one-time launch bolus. Combined branded sales of Revuforj and Niktimvo cleared one hundred fifteen million in the quarter, yet only the menin franchise and a profit share reach the income statement. The investment case turns on whether that mix, plus a convert-funded cash pile, funds a move into newly diagnosed acute myeloid leukemia before competition and royalty drag freeze the multiple.
Revuforj is in its sixth consecutive quarter of double-digit net revenue and prescription growth, and management attributes the latest step-up to patients staying on therapy after transplant rather than to a flood of new starts. Niktimvo, booked by Incyte, still grew but at a slower sequential pace, and Syndax only keeps half the commercial profit after cost of sales and selling expense. Royalty Pharma already takes a mid-teens slice of United States Niktimvo sales, so the cash that reaches Syndax is a residual of a residual. That structure is why reported revenue understates the brands and why the P&L still loses money even as the franchises annualize above two hundred million each.
Operating loss narrowed as selling expense rolled off last year's dual launch and research spend rose only with the frontline trials. Cash and investments ended June at five hundred seventy-five million after the June convertible issue, and management states that cash plus product, collaboration, and interest income funds the path to profitability. The market still prices the equity closer to a later-line hematology launch than to a frontline AML franchise. Does duration plus the fourth-quarter idiopathic pulmonary fibrosis and frontline chronic graft-versus-host readouts reopen that gap, or does Komzifti and a flattening new-start curve close it?